- (859) 257-1412 ext. 322
- 303B Sanders-Brown Building
University of Tennessee, Knoxville (2004), Concentration: Clinical Psychology
Allison Caban-Holt, Ph. D. continues to collect data on a grant from the Kentucky Science and Engineering Foundation for a study entitled “Investigation and Development of Portable Mobile Devices and Apps for Biofeedback Based Stress Reduction in Cognitively Impaired Populations”. The Mild Cognitive Impairment and exercise study (EXERT) a multi-site trial for which she is the site investigator for UK has successfully begun enrolling participants. She continues as a co-investigator of “Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease” which is one of the first anti-dementia trials to study individuals who do not have clinical signs of cognitive loss, but do exhibit changes in brain amyloid that suggest early risk for future dementia. She also continues as a co-investigator of the “Aging of Frontal Structure and Function in Down Syndrome and Dementia”. Dr. Caban-Holt has been collaborating with Drs. Daniela Moga, Lynne Eckmann, and Mark Huffmeyer to conduct follow-up evaluations on the study begun in 2009 looking at drug misuse in older adults. In 2017, Dr. Caban-Holt co-authored six manuscripts published, and has a book chapter on Down Syndrome in press in the Oxford Handbook of Adult Cognitive Disorders.
Dr. Caban-Holt’s research focuses on cognition, the behavioral effects of dementia, and detecting dementia through neuropsychological evaluation. Her research experience is quite varied; working on projects such as looking at sleep and agitation in dementia patients, investigating the potential protective effects of Vitamin E and selenium for the prevention of Alzheimer’s disease, and elucidating the challenges for African-American caregivers of dementia patients. Dr. Caban-Holt will be UK site investigator for an Alzheimer’s Disease Cooperative Study-sponsored clinical trial looking at home-based, self-administered assessment methods for identifying cognitive decline in health individuals over the age of 75.
Principal Investigator, Multi-center Trial to Evaluate Home-based Assessment Methods for Alzheimer’s Disease Prevention Research in People Over 75 Years Old, ADCS, 2007-2011.
Co-investigator, Unmet Needs of African-American Dementia Caregivers, Alzheimer’s Association, (2006-2007)
Postdoctoral Scholar, Prevention of Alzheimer’s disease by Vitamin E and Selenium, NIH/NIA, 5 R01 AG019241 (2001-2007)
Bottiggi, K., Salazar, J., Yu, L., Caban-Holt, A., Ryan, M., & Schmitt, F. (2007). Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: Impact on cognitive and physical functioning in Alzheimer’s disease. American Journal of Geriatric Psychiatry, 15(4), 357-9.
Bottiggi, K., Salazar, J., Yu, L., Caban-Holt, A., Ryan, M., Mendiondo, M. & Schmitt, F. (2006). Long-term cognitive impact of anticholinergic medications in older adults. American Journal of Geriatric Psychiatry, 14 (11), 980-4.
Caban-Holt, A., Mendiondo, M., Runyons, C., Kryscio, R., Markesbery, W., & Schmitt, F. (2006). Cognitive screening in the antioxidant AD prevention (PREADVISE) trial: Concordance of MIS and CERAD. Proceedings of the 10th International Conference on Alzheimer’s Disease and Related Disorders (ICAD). Madrid, Spain.
Caban-Holt, A., Schmitt, F.A., Runyons, C.R., Kryscio, R.J., Mendiondo, M.S., Sundquist, M.S., Markesbery, W.R., Coltman, C.A., Crowley, J.J., Goodman, P., & Hartline, J.A. (2006). Studying the effects of vitamin E and Selenium for Alzheimer’s disease prevention: the PREADVISE model. Research and Practice in Alzheimer’s Disease, 11, 124-130.
Caban-Holt, A., Bottiggi, K., & Schmitt, F.A. (2005). Measuring treatment response in Alzheimer’s disease clinical trials. Geriatrics, June 2005 Supplement, 60, 3-8.
Caban-Holt, A., Mattingly, M., Cooper, G., & Schmitt, F.A. (2005). Neurodegenerative memory disorders: A potential role of environmental toxins. Neurologic Clinics, 23, 485-521.